[1]苏亚峰 相萍萍 陈国芳 刘超.碘治疗Graves病的研究进展[J].国际内分泌代谢杂志,2019,39(01):21-24.[doi:10.3760/cma.j.issn.1673-4157.2019.01.005]
　Su Yafeng,Xiang Pingping,Chen Guofang,et al.Research progress of iodine in treating Graves' disease[J].International Journal of Endocrinology and Metabolism,2019,39(01):21-24.[doi:10.3760/cma.j.issn.1673-4157.2019.01.005]
点击复制

碘治疗Graves病的研究进展()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
39
期数:
2019年01期
页码:
21-24
栏目:
综述
出版日期:
2019-01-20

文章信息/Info

Title:
Research progress of iodine in treating Graves' disease
作者:
苏亚峰 相萍萍 陈国芳 刘超
南京中医药大学附属中西医结合医院内分泌代谢病院区,江苏省中医药研究院 210028
Author(s):
Su Yafeng;  Xiang Pingping;  Chen Guofang;  Liu Chao
Endocrine and Diabetes Center, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210028, China
关键词:
Graves病;  碘;  有效性;  安全性
Keywords:
Graves' disease;  Iodine;  Efficacy;  Safety
DOI:
10.3760/cma.j.issn.1673-4157.2019.01.005
摘要:
Graves病的主要治疗方法包括抗甲状腺药物(ATD)、131I、手术等,但存在缓解率低、复发率高、长期疗效不满意等诸多问题。近来研究显示,高碘制剂治疗Graves病可以快速控制甲状腺激素,缓解甲状腺功能亢进症,且联合ATD时能够发挥减毒增效的作用,提示碘制剂可能在Graves病的治疗中扮演更重要的角色。但目前各项研究的样本量较小,覆盖的国家、地区局限,碘营养状况单一,碘制剂的应用剂量及疗程不一,仍需更多高质量的研究进一步明确碘制剂治疗Graves病的有效性与安全性。
Abstract:
Main treatment of Graves' disease includes anti-thyroid drugs(ATD), 131I therapy and surgery, but each method remains many shortcomings such as low remission and high recurrence rate, unsatisfactory long-term efficacy, etc. Recently, the research on the treatment of Graves' disease has shown that iodine can quickly control thyroid hormones and relieve hyperthyroidism. And combined with ATD may reduce ATD's toxicity and enhance efficacy. It suggests that iodine may play a more important role in the treatment of Graves' disease.However, at present, the sample size of each study is small, the coverage of countries and regions are limited, the nutritional status of iodine is monotonous, and the application of iodine preparation has different dose and period of treatment. There is still a need for more high-quality research to further clarify the effectiveness and safety of iodine in the treatment of Graves' disease.

参考文献/References:

[1] Shan Z,Chen L,Lian X,et al.Iodine status and prevalence of thyroid disorders after introduction of mandatory universal salt iodization for 16 years in China: a cross-sectional study in 10 cities[J].Thyroid,2016,26(8):1125-1130.DOI:10.1089/thy.2015.0613.
[2] Burch HB,Burman KD,Cooper DS.A 2011 survey of clinical practice patterns in the management of Graves' disease[J].J Clin Endocrinol Metab,2012,97(12):4549-4558. DOI:10.1210/jc.2012-2802.
[3] 中华医学会内分泌学分会《中国甲状腺疾病诊治指南》编写组. 中国甲状腺疾病诊治指南——甲状腺功能亢进症[J]. 中华内科杂志,2007,46(10):876-882. DOI:10.3760/j.issn:0578-1426.2007.10.035.
[4] Astwood EB. Thyroid and antithyroid drugs. In: Goodman LS, Gilman A, eds. The pharmacological basis of therapeutics. 3rd ed. New York: The Macmillan Company. 1965:1466-1503.
[5] Thompson WO, Thompson PK, Brailey AG, et al. Prolonged treatment of exophthalmic goiter by iodine alone[J]. Arch Intern Med,1930,(45):481-502.
[6] Woeber KA.Iodine and thyroid disease[J].Med Clin North Am,1991,75(1):169-178.
[7] Markou K,Georgopoulos N,Kyriazopoulou V,et al.Iodine-induced hypothyroidism[J].Thyroid,2001,11(5):501-510.DOI:10.1089/105072501300176462.
[8] Gottlieb A,Krueger JG,Bright R,et al.Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis[J].J Am Acad Dermatol,2000,42(3):428-435.
[9] Eng PH,Cardona GR,Fang SL,et al.Escape from the acute Wolff-Chaikoff effect is associated with a decrease in thyroid sodium/iodide symporter messenger ribonucleic acid and protein[J]. Endocrinology,1999,140(8):3404-3410.DOI:10.1210/endo.140.8.6893.
[10] 徐韬,安家璈,胡俊峰. 高碘致甲状腺损伤的机制研究进展[J]. 《国外医学(卫生学分册)》, 2003, 30(6):337-342.
[11] Calissendorff J, Falhammar H. Lugol's solution and other iodide preparations: perspectives and research directions in Graves' disease[J]. Endocrine,2017,58(3):467-473.DOI:10.1007/s12020-017-1461-8.
[12] Ross DS,Burch HB,Cooper DS,et al.2016 American thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis[J].Thyroid,2016,26(10):1343-1421.DOI:10.1089/thy.2016.0229.
[13] Uchida T,Goto H,Kasai T,et al.Therapeutic effectiveness of potassium iodine in drug-naïve patients with Graves' disease: a single-center experience[J].Endocrine,2014,47(2):506-511.DOI:10.1007/s12020-014-0171-8.
[14] Okamura K,Sato K,Fujikawa M,et al.Remission after potassium iodide therapy in patients with Graves' hyperthyroidism exhibiting thionamide-associated side effects[J]. J Clin Endocrinol Metab,2014,99(11):3995-4002.DOI:10.1210/jc.2013-4466.
[15] Sato S,Noh JY,Sato S,et al.Comparison of efficacy and adverse effects between methimazole 15 mg+inorganic iodine 38 mg/day and methimazole 30 mg/day as initial therapy for Graves' disease patients with moderate to severe hyperthyroidism[J].Thyroid,2015,25(1):43-50.DOI:10.1089/thy.2014.0084.
[16] Takata K,Amino N,Kubota S,et al.Benefit of short-term iodide supplementation to antithyroid drug treatment of thyrotoxicosis due to Graves' disease[J].Clin Endocrinol(Oxf),2010,72(6):845-850.DOI:10.1111/j.1365-2265.2009.03745.x.
[17] Yoshihara A,Noh JY,Watanabe N,et al.Substituting potassium iodide for methimazole as the treatment for Graves' disease during the first trimester may reduce the incidence of congenital anomalies: a retrospective study at a single medical institution in Japan[J].Thyroid,2015,25(10):1155-1161.DOI:10.1089/thy.2014.0581.
[18] Alexander EK,Pearce EN,Brent GA,et al.2017 Guidelines of the American thyroid association for the diagnosis and management of thyroid disease during pregnancy and the postpartum[J].Thyroid,2017,27(3):315-389.DOI:10.1089/thy.2016.0457.
[19] Jeong KU,Lee HS,Hwang JS.Effects of short-term potassium iodide treatment for thyrotoxicosis due to Graves' disease in children and adolescents[J].Ann Pediatr Endocrinol Metab,2014,19(4):197-201.DOI:10.6065/apem.2014.19.4.197.
[20] Emerson CH,Anderson AJ,Howard WJ,et al.Serum thyroxine and triiodothyronine concentrations during iodide treatment of hyperthyroidism[J].J Clin Endocrinol Metab,1975,40(1):33-36.DOI:10.1210/jcem-40-1-33.
[21] Nagataki S,Shizume K,Nakao K.Effect of iodide on thyroidal iodine turnover in hyperthyroid subjects[J].J Clin Endocrinol Metab,1970,30(4):469-478.DOI:10.1210/jcem-30-4-469.

相似文献/References:

[1]贾媛媛,陈莉丽.Th17细胞与Graves病及桥本甲状腺炎[J].国际内分泌代谢杂志,2014,(05):344.[doi:10.3760/cma.j.issn.1673-4157.2014.05.016]
　Jia Yuanyuan,Chen Lili.Relationship between Th17 cells and Graves' disease,Hashimoto's thyroiditis[J].International Journal of Endocrinology and Metabolism,2014,(01):344.[doi:10.3760/cma.j.issn.1673-4157.2014.05.016]
[2]房方,卫红艳,王坤玲,等.硒治疗自身免疫性甲状腺疾病的荟萃分析[J].国际内分泌代谢杂志,2016,36(04):247.[doi:10.3760/cma.j.issn.1673-4157.2016.04.09]
　Fang Fang,Wei Hongyan,Wang Kunling,et al.A meta-analysis of selenium in the treatment of autoimmune thyroid diseases[J].International Journal of Endocrinology and Metabolism,2016,36(01):247.[doi:10.3760/cma.j.issn.1673-4157.2016.04.09]
[3]郑仁东,刘超.白细胞介素-6与甲状腺疾病[J].国际内分泌代谢杂志,2016,36(05):352.[doi:10.3760/cma.j.issn.1673-4157.2016.05.18]
　Zheng Rendong,Liu Chao.Interleukin-6 and thyroid disease[J].International Journal of Endocrinology and Metabolism,2016,36(01):352.[doi:10.3760/cma.j.issn.1673-4157.2016.05.18]
[4]郑慧娟,魏璠,魏军平.自噬与自身免疫性甲状腺疾病[J].国际内分泌代谢杂志,2017,37(01):17.[doi:10.3760/cma.j.issn.1673-4157.2017.01.05]
　Zheng Huijuan,Wei Fan,Wei Junping..Autophagy and autoimmune thyroid disease[J].International Journal of Endocrinology and Metabolism,2017,37(01):17.[doi:10.3760/cma.j.issn.1673-4157.2017.01.05]
[5]浮迎迎,刘超,蔡可英.肠道菌群与甲状腺稳态的关系[J].国际内分泌代谢杂志,2017,37(02):98.[doi:10.3760/cma.j.issn.1673-4157.2017.02.007]
　Fu Yingying*,Liu Chao,Cai Keying..Relationship between intestinal bacteria and thyroid homeostasis[J].International Journal of Endocrinology and Metabolism,2017,37(01):98.[doi:10.3760/cma.j.issn.1673-4157.2017.02.007]
[6]黄慧 胡欣 徐一娇 刘超.利妥昔单克隆抗体治疗Graves病的作用机制[J].国际内分泌代谢杂志,2018,38(02):121.[doi:10.3760/cma.j.issn.1673-4157.2018.02.013]
　Huang Hui,Hu Xin,Xu Yijiao,et al.Mechanism of rituximab in the treatment of Graves' disease[J].International Journal of Endocrinology and Metabolism,2018,38(01):121.[doi:10.3760/cma.j.issn.1673-4157.2018.02.013]
[7]赫晓晴 单忠艳.肠道菌群与自身免疫性甲状腺疾病[J].国际内分泌代谢杂志,2020,40(03):179.[doi:10.3760/cma.j.issn.1673-4157.2020.03.008]
　He Xiaoqing,Shan Zhongyan.Gut microbiota and autoimmune thyroid disease[J].International Journal of Endocrinology and Metabolism,2020,40(01):179.[doi:10.3760/cma.j.issn.1673-4157.2020.03.008]
[8]刘天琪,张秀英,纪立农.促甲状腺激素受体抗体的检测及应用进展[J].国际内分泌代谢杂志,2021,41(01):5.[doi:10.3760/cma.j.cn121383-20200608-06021]
　Liu Tianqi,Zhang Xiuying,Ji Linong..Progression of assay and clinical practice of thyroid stimulating hormone receptor antibody[J].International Journal of Endocrinology and Metabolism,2021,41(01):5.[doi:10.3760/cma.j.cn121383-20200608-06021]
[9]龙丽 张秀英 纪立农.甲状腺相关眼病治疗新希望——IGF-Ⅰ受体拮抗剂[J].国际内分泌代谢杂志,2022,42(04):256.[doi:10.3760/cma.j.cn121383-20210420-04055]
　Long Li,Zhang Xiuying,Ji Linong..New hope for the treatment of thyroid associated orbitopathy-IGF-Ⅰ receptor antagonist[J].International Journal of Endocrinology and Metabolism,2022,42(01):256.[doi:10.3760/cma.j.cn121383-20210420-04055]

备注/Memo

备注/Memo:
通信作者:刘超,Email:liuchao@nfmcn.com
Corresponding author: Liu Chao, Email:liuchao@nfmcn.com
更新日期/Last Update: 2019-01-20